These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 16101195)

  • 1. Urinary levels of vascular endothelial growth factor in patients with prostate cancer as a predictor of disease progression.
    Miyake H; Muramaki M; Kurahashi T; Yamanaka K; Hara I
    Anticancer Res; 2005; 25(5):3645-9. PubMed ID: 16101195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy.
    Shariat SF; Anwuri VA; Lamb DJ; Shah NV; Wheeler TM; Slawin KM
    J Clin Oncol; 2004 May; 22(9):1655-63. PubMed ID: 15117988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy.
    Chan LW; Moses MA; Goley E; Sproull M; Muanza T; Coleman CN; Figg WD; Albert PS; Ménard C; Camphausen K
    J Clin Oncol; 2004 Feb; 22(3):499-506. PubMed ID: 14752073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implication of vascular endothelial growth factor T-460C polymorphism in the risk and progression of prostate cancer.
    Fukuda H; Tsuchiya N; Narita S; Kumazawa T; Horikawa Y; Inoue T; Saito M; Yuasa T; Matsuura S; Satoh S; Ogawa O; Habuchi T
    Oncol Rep; 2007 Nov; 18(5):1155-63. PubMed ID: 17914566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer.
    George DJ; Regan MM; Oh WK; Tay MH; Manola J; Decalo N; Duggan S; Dewolf WC; Kantoff PW; Bubley GJ
    Urology; 2004 Feb; 63(2):327-32. PubMed ID: 14972483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic value of vascular endothelial growth factor (VEGF)-A and its receptor in clinically localized prostate cancer: a prospective evaluation in 100 patients undergoing radical prostatectomy.
    Mao K; Badoual C; Camparo P; Delongchamps NB; Vieillefond A; Dinh-Xuan AT; Peyromaure M
    Can J Urol; 2008 Oct; 15(5):4257-62. PubMed ID: 18814815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of major heat shock proteins in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
    Kurahashi T; Miyake H; Hara I; Fujisawa M
    J Urol; 2007 Feb; 177(2):757-61. PubMed ID: 17222676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum level of cathepsin B and its density in men with prostate cancer as novel markers of disease progression.
    Miyake H; Hara I; Eto H
    Anticancer Res; 2004; 24(4):2573-7. PubMed ID: 15330217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of serum macrophage migration inhibitory factor in men with prostate cancer as a novel biomarker of detection and disease progression.
    Muramaki M; Miyake H; Yamada Y; Hara I
    Oncol Rep; 2006 Jan; 15(1):253-7. PubMed ID: 16328065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma levels and expression of vascular endothelial growth factor-A in human localized prostate cancer.
    Peyromaure M; Badoual C; Camparo P; Grabar S; Goulvestre C; Fulla Y; Vieillefond A; Mao K; Dinh-Xuan AT
    Oncol Rep; 2007 Jul; 18(1):145-9. PubMed ID: 17549360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The expression of vascular endothelial growth factor is associated with the risk of cancer progression after radical prostatectomy.
    Peyromaure M; Camparo P; Badoual C; Descazeaud A; Dinh-Xuan AT
    BJU Int; 2007 May; 99(5):1150-3. PubMed ID: 17437444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxidative DNA damage in patients with prostate cancer and its response to treatment.
    Miyake H; Hara I; Kamidono S; Eto H
    J Urol; 2004 Apr; 171(4):1533-6. PubMed ID: 15017214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinicopathological significance of neoadjuvant hormonal therapy prior to radical prostatectomy: whole section analysis].
    Uemura H; Cho M; Hirao Y; Konishi N
    Hinyokika Kiyo; 2002 Nov; 48(11):719-23. PubMed ID: 12512148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of micrometastases in pelvic lymph nodes detected by real-time reverse transcriptase polymerase chain reaction in patients with clinically localized prostate cancer undergoing radical prostatectomy after neoadjuvant hormonal therapy.
    Miyake H; Kurahashi T; Hara I; Takenaka A; Fujisawa M
    BJU Int; 2007 Feb; 99(2):315-20. PubMed ID: 17155986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced expression of heat shock protein 27 following neoadjuvant hormonal therapy is associated with poor clinical outcome in patients undergoing radical prostatectomy for prostate cancer.
    Miyake H; Muramaki M; Kurahashi T; Yamanaka K; Hara I; Fujisawa M
    Anticancer Res; 2006; 26(2B):1583-7. PubMed ID: 16619575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of clusterin in prostate cancer correlates with Gleason score but not with prognosis in patients undergoing radical prostatectomy without neoadjuvant hormonal therapy.
    Miyake H; Muramaki M; Kurahashi T; Yamanaka K; Hara I; Gleave M; Fujisawa M
    Urology; 2006 Sep; 68(3):609-14. PubMed ID: 16979705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum cathepsin D and its density in men with prostate cancer as new predictors of disease progression.
    Hara I; Miyake H; Yamanaka K; Hara S; Kamidono S
    Oncol Rep; 2002; 9(6):1379-83. PubMed ID: 12375052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
    Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
    J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.
    Shariat SF; Abdel-Aziz KF; Roehrborn CG; Lotan Y
    Eur Urol; 2006 Feb; 49(2):293-302. PubMed ID: 16387412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radical prostatectomy for clinical T4 prostate cancer.
    Johnstone PA; Ward KC; Goodman M; Assikis V; Petros JA
    Cancer; 2006 Jun; 106(12):2603-9. PubMed ID: 16700037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.